Sclurnge i agree few very interesting points in the interview & i guess in relation to point iii) aside from the candidate previously showing promise in TBI/stroke last year & new patent granted recently it maybe shows a glimmer that they're moving on out-licensing CD40 finally ? Should hopefully provide some exciting developments later this year though.
I guess secondly management now indicating they're willing to explore options to co-develop some candidates implies that they're confident in moving to cash sustanability in the not to distant future with excess funds to throw around ? From memory the decision to remain pre-clinical as was the purpose i guess of resturcturing the companies business model was to substantially mitigate risk as it was all bourne by the partners but once the company becomes cash generative i guess it is then in a position to take a portion of the risk back under it's belt for potentially much higher returns should candidates prove succesful. I deal time to start moving out some internal candidates with decent claws left in them though.
Hopefully things will be looking very different come end of year & patience will be rewarded, still not counting beans quite yet though :-)
PYC Price at posting:
4.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)